DLL3 in SCLC: Module

CME

Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 12, 2023

Expiration: April 11, 2024

Hossein Borghaei
Hossein Borghaei, MS, DO

Activity

Progress
1
Course Completed

References

  1. Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016;5:26-38.
  2. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
  3. Union for International Cancer Control (UICC). GLOBOCAN 2020: new global cancer data. uicc.org/news/globocan-2020-new-global-cancer-data. Accessed March 29, 2023.
  4. Yao J, Bergsland E, Aggarwal R, et al. DLL3 as an emerging target for the treatment of neuroendocrine neoplasms. Oncologist. 2022;27:940-951.
  5. Leonetti A, Facchinetti F, Minari R, et al. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Cell Oncol (Dordr). 2019;42:261-273.
  6. Sahlgren C, Lendahl U. Notch signaling and its integration with other signaling mechanisms. Regen Med. 2006;1:195-205. 
  7. Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289-297.
  8. Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.
  9. Owen DH, Giffin MJ, Bailis JM, et al. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12:61. 
  10. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526-1537.
  11. Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;[Online ahead of print].
  12. Johnson ML, Dy GK, Mamdani H, et al. Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 8566.